Aims/hypothesis Many cystic fibrosis patients are vitamin D-insufficient. Cystic fibrosis-related diabetes is a major complication of cystic fibrosis. The literature suggests that vitamin D might possess certain glucose-lowering properties. We aimed to assess the relationship between vitamin D and cystic fibrosis-related glucose intolerance. Methods We enrolled 898 cystic fibrosis patients from Sweden, Norway and Denmark. Vitamin D intake was assessed using a seven-day food record. Serum 25-hydroxyvitamin D (s25OHD) and HbA 1c were measured, and an OGTT was carried out. Multiple linear and logistic regressions were used for HbA 1c and cystic fibrosis-related diabetes/OGTT result as outcome variables, respectively. Each model was controlled for country, and for known cystic fibrosis-related diabetes risk factors: age, sex, genotype, liver dysfunction, long-term corticosteroid treatment, and lung and pancreatic function. Results Degree of vitamin D insufficiency (OR 1.36; p=0.032) and s25OHD<30 nmol/l (OR 1.79; p=0.042) were significant risk factors for cystic fibrosis-related diabetes. Accordingly, HbA 1c value was positively associated with s25OHD< 30 nmol/l and<50 nmol/l, as well as with degree of vitamin D insufficiency (adjusted R 2 =20.5% and p<0.05 in all).
Introduction
Cystic fibrosis is the most common life-shortening autosomal recessive condition in people of European descent [1] . The most frequently appearing disease-causing mutation is F508del. The affected gene codes for a chloride channel situated on membranes of epithelial cells. Thus, its defect results in inappropriately thick mucus and malfunctioning of epithelial organs, such as lungs, pancreas and liver [2] . The major cause of morbidity and mortality is progressive pulmonary disease associated with chronic bacterial infection and inflammation [3] .
The majority of children and adults with cystic fibrosis worldwide are vitamin D insufficient, irrespective of their exocrine pancreatic function [4] [5] [6] [7] . However, there is as yet no evidence for a benefit of vitamin D supplementation in cystic fibrosis, not even for bone health [8] . Many in vitro and clinical descriptive studies support a role for vitamin D in the pathogenesis of both type 1 and type 2 diabetes, which have been reviewed in detail elsewhere [9] . Vitamin D supplementation has been associated with a decreased incidence of type 1 diabetes [10] and plasma 25-hydroxyvitamin D (25OHD) has been described as being associated with type 2 diabetes [11] . The exact molecular pathways are not completely understood but vitamin D has been suggested to act via its immunomodulatory effects in type 1 diabetes [12, 13] and to increase insulin secretion and peripheral insulin sensitivity in type 2 diabetes [14, 15] .
With improving medical care, survival increases and long-term complications of cystic fibrosis become more prevalent. The most common complication is cystic fibrosis-related diabetes (CFRD), with a prevalence of 33% in some populations of patients with cystic fibrosis [16] . CFRD is associated with inferior lung function and earlier death [16] [17] [18] [19] . The loss of pancreatic beta cells as a result of pancreatic fibrosis is thought to be one of the principal causes of diabetes in cystic fibrosis, but its aetiology remains unclear. It clearly shares pathological features both with type 1 and type 2 diabetes [20] . It is generally agreed that CFRD primarily results from an insulin-insufficient state, which is aggravated by worsening insulin resistance [21] .
Therefore, it is reasonable to hypothesise that the known high prevalence of vitamin D insufficiency in patients with cystic fibrosis may represent a risk factor for the development of CFRD. To the best of our knowledge, there are no reports on the relation between vitamin D and CFRD. Simultaneously, the high prevalence of both diabetes mellitus and vitamin D insufficiency among patients with cystic fibrosis renders this population suitable for studying the suggested glucose-lowering effect of vitamin D. We therefore examined the associations of vitamin D intake and vitamin D status with HbA 1c , diagnosis of CFRD, OGTT result and HbA 1c -defined diabetes mellitus in a welldefined cohort of Scandinavian patients with cystic fibrosis.
Methods
Study cohort This study used data collected in the Scandinavian Cystic Fibrosis Nutritional Study. It is a cross-sectional multi-centre study, in which seven cystic fibrosis centres (Stockholm, Gothenburg, Lund, Uppsala, Copenhagen, Oslo and Bergen) enrolled 898 patients with cystic fibrosis during an inclusion period from 5 September 2003 to 25 May 2006. The study was approved by the regional ethics committees in each country. All the adult patients and parents of all the paediatric patients gave informed written consent. In the nutritional study we previously assessed the relationship between vitamin D and serum total IgG [22] . We now used the data collected to analyse vitamin D as a possible risk factor for CFRD.
Vitamin D intake assessment A 7 day food record was used to quantify daily food vitamin D intake in patients ≥4 years of age (406 patients). A dietitian specialising in cystic fibrosis provided instructions on how to complete the nationally designed and validated pre-coded forms. Response rates were 76-86% [22] . The food records have been described in detail previously [22] [23] [24] .
Dietitians calculated daily supplemented vitamin D intake from the intake of various vitamin and mineral supplements (730 patients). At the time of the study there was no uniform vitamin D supplementation policy and serum 25OHD (s25OHD) was not monitored. Vitamin D was given in the form of various multivitamin preparations, sometimes combined with a more specific vitamin D supplement or fish liver oil. Total vitamin D intake per day was quantified as daily food plus daily supplemented vitamin D intake (389 patients). All vitamin D intake variables were further adjusted to vitamin D intake per kg body weight, to adjust for the large variation in patients' body weight (6.1-131.0 kg). s25OHD and vitamin D insufficiency classification Serum vitamin D was measured as s25OHD at inclusion. All the collected samples were analysed at the Research Laboratory, Department of Paediatrics, Haukeland University Hospital in Bergen. A modified version of highperformance liquid chromatography with a UV detection method, described by Aksnes, was used [25] . The method determines the sum of 25OHD 2 and 25OHD 3, and provides results that are comparable with radioimmunoassay or liquid chromatography-tandem mass spectrometry [26, 27 ; L. Aksnes, personal communication] .
s25OHD was used as a measure of vitamin D status, and four degrees of vitamin D insufficiency were defined according to s25OHD (nmol/l) as follows: s25OHD≥75 (degree 0); 50≤s25OHD<75 (degree 1); 30≤s25OHD<50 (degree 2); s25OHD<30 (degree 3). In addition, all patients were classified either as '0' (being above) or as '1' (being below) with respect to the following cut-offs for s25OHD: 30, 50, and 75 nmol/l. We have chosen these cut-offs because they have been suggested to be associated with increased risk of various conditions in a number of studies [28] .
CFRD, glucose tolerance and HbA 1c -defined diabetes mellitus A 75 g OGTT was performed at inclusion in a randomly chosen subgroup of patients who were ≥9 years of age (n=466). OGTT was classified as pathological if 2 h plasma glucose was ≥7.8 mmol/l, thus including patients with both impaired glucose tolerance and CFRD.
Criteria for CFRD diagnosis were: fasting plasma glucose ≥7.0 mmol/l at two occasions, or 2 h plasma glucose during OGTT≥11.1 mmol/l at inclusion or any time during follow up at the respective centres. Thus, the group of patients with CFRD includes patients diagnosed by OGTT in the clinic before inclusion in the study ('known CFRD'), and patients diagnosed by OGTT at inclusion ('new CFRD diagnosed by OGTT'). Primarily, the whole group of CFRD patients was analysed, and secondarily the two subgroups were analysed separately for comparison. In patients younger than 9 years of age, the potential presence/absence of CFRD was assessed anamnestically, and OGTT was carried out only in cases where anamnesis raised suspicion of CFRD.
For study purposes, HbA 1c >6.5% (>47.5 mmol/mol) at inclusion in patients who had not previously been diagnosed with and treated for diabetes, was used as another criterion for the diagnosis of diabetes ('new DM diagnosed by HbA 1c ').
HbA 1c was measured as per cent of total haemoglobin by ion exchange chromatography with high-performance liquid chromatography at the respective hospital laboratories. The only centre using a different method was Oslo, where HbA 1c was measured at the Department for Medical Biochemistry, Oslo University Hospital, by an immunological method (Tina-quant, Roche Diagnostics, Basel, Switzerland). Swedish centres used the Mono S level, while Norwegian and Danish centres used the international National Glycohaemoglobin Standardization Program (NGSP)/ DCCT standard. Therefore, Swedish HbA 1c values were transformed using the following formula: HbA 1c (NGSP) (%)=0.956×HbA 1c (Mono S) (%)+1.182.
Confounding factors All variables included in the multiple linear or logistic regression analyses as independent variables were assessed at inclusion in the study. Patients using pancreatic enzymes were classified as pancreatic insufficient. Patients on treatment with ursodeoxycholic acid or those having pathological plasma alanine aminotransferase (ALT) concentration (>0.76 μkat/l in women, >1.20 μkat/l in men) were classified as having liver dysfunction. Long-term corticosteroid treatment was classified as 'Yes' if it was being given at the time of inclusion in a longterm manner, either by mouth or inhalation. A lung function test was performed in patients ≥7 years of age using dynamic spirometry at each centre. From measured forced expiratory volume in 1 s (FEV1), per cent predicted values were calculated using Solymar and Quanjer reference equations for patients <19 and ≥19 years, respectively [29, 30] .
Statistical analysis Because HbA 1c values had positively skewed distribution, we log-transformed them (using base e). Categorical variables were coded (sex male 0/female 1; F508del homozygous genotype 0/other genotypes 1; all other variables: no 0/yes 1 [ Table 1 ]). The variable 'country' was coded using two dummy variables (Sweden 0-0; Norway 1-0; Denmark 0-1). Some centres were too small to be used in the statistical analysis and therefore we have controlled for the centre effect by collapsing centres among countries; i.e. variation between countries was used to estimate centre effect. All analyses were primarily conducted for the whole patient dataset (N=898); secondarily the subgroup of children (n=442) and the subgroup of adults (n=456) were analysed separately.
Univariate linear regression analysis was used to examine the relation between vitamin D status or intake, and HbA 1c . Multiple linear regression (MLR) analyses were performed for HbA 1c as dependent variable, and s25OHD, degree of vitamin D insufficiency, s25OHD<30 nmol/l, s25OHD<50 nmol/l, s25OHD<75 nmol/l, and food and supplemented vitamin D sources of intake as independent variables, each entered separately in various MLR models.
To evaluate differences in vitamin D status or intake, an independent t test or Mann-Whitney U Test was performed. To compare proportions, a χ 2 test was applied. Logistic regression analysis was used to further assess the associations of vitamin D intake or status with CFRD, OGTT or HbA 1c -defined diabetes. Each MLR or logistic regression model was controlled for country, sex, genotype, age, pancreatic function, FEV1 (% predicted), liver dysfunction, and long-term corticosteroid treatment.
Statistical analyses used STATISTICA (version 10). All tests were two-sided and p<0.05 was considered statistically significant.
Results
Among the 898 Scandinavian patients with cystic fibrosis aged 0.29-65.9 years, mean s25OHD was 52.0 nmol/l (range 1.5-206.9 nmol/l). In this patient dataset, s25OHD levels were not determined by latitude zone (zone 1: 54°-59°; zone 2: 60°-65°; zone 3: 66°-71°north), dark (23 September to 19 March) or light (20 March to 22 September) part of the year, or by belonging to a specific cystic fibrosis centre (NS). Median HbA 1c was 5.6% (37.7 mmol/mol) and the majority of the patients had physiological OGTT results ( Table 1 ). The adult subpopulation had inferior lung function, greater prevalence of complications including CFRD, and had lower vitamin D intake than the paediatric subpopulation (ESM Table 1 ).
In the whole patient dataset, univariate linear regression analyses showed significant positive associations between HbA 1c and s25OHD, s25OHD<30 nmol/l, s25OHD< 50 nmol/l, and degree of vitamin D insufficiency, and significant negative associations between HbA 1c and supplemented vitamin D intake per kg body weight and total vitamin D intake per kg body weight. Subgroup analyses for children and adults separately have shown that vitamin D status was associated with HbA 1c in the paediatric subpopulation only (ESM Table 2 ). We further analysed the whole patient dataset using MLR analysis. In the MLR model of HbA 1c controlled for country, age, sex, genotype, lung function, long-term corticosteroid treatment, pancreatic insufficiency, and liver dysfunction, associations remained statistically significant with s25OHD<30 nmol/l (ESM Table 3 ), s25OHD<50 nmol/l, and vitamin D insufficiency degree as independent variables (Table 2) Table 4 ).
Patients with CFRD at inclusion had lower s25OHD, total vitamin D intake, and supplemented and total vitamin D intake per kg body weight than non-diabetic patients. Subgroup analyses showed that patients with known CFRD, as opposed to new CFRD, had low vitamin D intake. However, the two subgroups did not differ in s25OHD (low in both). Accordingly, patients with pathological OGTT results had lower s25OHD than patients with physiological OGTT results. Patients with HbA 1c -defined diabetes had lower supplemented and total vitamin D intake per kg body weight than patients not meeting the definition of diabetes according to HbA 1c (ESM Table 5 ).
The χ 2 test confirmed that inferior serum vitamin D status is associated with a greater proportion of patients with CFRD, both known and new, pathological OGTT results, or HbA 1c -defined diabetes (ESM Table 6 ). In the logistic regression model we controlled for potential confounders: country, age, sex, genotype, lung function, long-term corticosteroid treatment, pancreatic insufficiency, and liver dysfunction. In this model, s25OHD<30 nmol/l and degree of vitamin D insufficiency remained significantly associated with CFRD (Table 3 and ESM Table 7 ). Similarly, s25OHD< 50 nmol/l was associated with CFRD, but statistical significance was not reached (p=0.058; Table 3 ). There was no association between vitamin D and the two CFRD subgroups (known and new CFRD). Neither pathological OGTT nor HbA 1c -defined diabetes showed any association with vitamin D in multivariate logistic regression analysis (ESM Table 8 ). Since all but 14 diabetic patients were adults, we did not carry out subgroup analyses for children and adults separately.
Discussion
Here we show that vitamin D status is associated with HbA 1c and CFRD diagnosis in a large cohort of welldefined Scandinavian patients with cystic fibrosis. This is the first report on a relationship between vitamin D and diabetes in a population of patients with cystic fibrosis. Our study leads us to hypothesise that improving vitamin D status in cystic fibrosis patients may have some glucoselowering effect. Interestingly, our results indicate that the effect might be more relevant in the population of children, compared with adults.
Over the past decade, increasing animal and human data in the literature has been suggesting that vitamin D deficiency plays a role in the pathophysiology of diabetes BW, body weight mellitus. Support exists for the hypothesis of a relationship between hypovitaminosis D and type 2 diabetes, overweight, hypertension, heart infarction and stroke [31] [32] [33] [34] [35] , exerting its effect via influencing inflammatory atherosclerotic processes [36] , peripheral insulin sensitivity and beta cell function [14] . Lower vitamin D levels were found to be associated with insulin resistance and increase in HbA 1c [37, 38] . In type 1 diabetes, vitamin D is proposed to act through immunological mechanisms by downregulation of dendritic cells and T helper 1 lymphocytes, suppression of antigen-presenting capacity of macrophages and promotion of T helper 2 lymphocytes [31] . CFRD is a unique type of diabetes. Its complete aetiology remains unclear. However, it is known that CFRD is characterised primarily by insulin deficiency and secondarily by insulin resistance [20, 21] . Therefore, vitamin D might theoretically exert certain glucose-lowering effects even in this type of diabetes. The results of our study support this hypothesis. Indeed, in univariate analyses, both vitamin D status and intake were associated with HbA 1c values. Accordingly, CFRD patients had inferior vitamin D status and lower vitamin D intake than nondiabetic patients and degree 3 of vitamin D insufficiency was associated with CFRD, pathological OGTT result and HbA 1c -defined diabetes.
HbA 1c mirrors the long-term glycaemic exposure in patients with or without diabetes. In our study we used it as a proxy for glucose homeostasis. Therefore, in the MLR model we corrected for factors that were previously shown to be independently associated with increased risk of impaired glucose homeostasis and additional diagnosis of diabetes in cystic fibrosis. These are genotype [39] , increasing age, female sex, inferior pulmonary function, liver dysfunction, pancreatic insufficiency, and long-term oral or inhalatory corticosteroid use [40] . To account for the potential differences between the participating countries, the 'country' variable was included in the MLR model as an independent variable.
In our MLR models we have confirmed age, lung function, pancreatic insufficiency, country, s25OHD<30 nmol/l, s25OHD<50 nmol/l and degree of vitamin D insufficiency as significant determinants of HbA 1c values in the Scandinavian cystic fibrosis patients. Similarly, in the logistic regression model that used the same independent variables as the MLR models, risk factors for CFRD were confirmed to be age, lung function, pancreatic insufficiency, country, s25OHD<30 nmol/l and vitamin D insufficiency degree. These results are in line with several other studies exploring risk factors for CFRD. However, the findings of s25OHD<30 nmol/l, s25OHD<50 nmol/l and degree of vitamin D insufficiency as significant independent risk factors for higher HbA 1c values and diagnosis of CFRD are novel and indicate for the first time that vitamin D may play a role both in glucose homeostasis in cystic fibrosis patients as well as in the development of CFRD.
Worldwide, the currently used vitamin D supplementation regimen has not been able to correct vitamin D insufficiency in cystic fibrosis [7] . This was confirmed in our study, since the vast majority of the patients included had suboptimal s25OHD despite the fact that the median daily total vitamin D intake approached doses previously shown to have a beneficial effect on bone health in certain populations [41] . However, there is yet no evidence of benefit of vitamin D supplementation in cystic fibrosis [8] . Thus, our findings are significant since they deliver a hypothesis of a novel field of importance of vitamin D in cystic fibrosis and strongly substantiate prospective intervention studies. In the end, this may also help to outline future prevention and treatment strategies for CFRD. Important to note, the subgroup analyses for HbA 1c have shown that the observed associations are accounted for by associations in the population of children only. This is in line with animal studies [42, 43] and several other human epidemiological studies [44] [45] [46] that point to the importance of vitamin D in early childhood. Our data indicate that vitamin D supplementation may be most beneficial during childhood even in cystic fibrosis patients. We speculate that children with cystic fibrosis have more preserved insulin secretion and greater peripheral insulin sensitivity as a result of lower inflammation grade, thus having greater potential for the glucose-lowering effect of vitamin D.
Interestingly, our multivariate models showed associations between HbA 1c /diabetes and serum vitamin D status, but not vitamin D intake. We speculate that vitamin D intake may be strongly dependent on adherence with cystic fibrosis treatment, and by correcting for lung function, a probable partial correlate of adherence in cystic fibrosis patients, the associations seen in uncorrected univariate analyses disappear. On the other hand, s25OHD is not as strongly determined by adherence; other important determinants of variation in s25OHD are sun exposure and genetic background, determining the efficacy of vitamin D uptake from the gut and hydroxylation process.
By including lung function in the MLR model, we may have partially corrected for the potential confounding effect of adherence. However, since there is no existing clear measure of adherence to treatment in cystic fibrosis, complete correction for adherence is impossible. Thus, adherence as a hypothetical confounder cannot be fully ruled out.
The Scandinavian Cystic Fibrosis Nutritional Study was not designed for the specific study of diabetes; thus we do not have data on C-peptide, fasting plasma glucose, peripheral insulin sensitivity or the gas chromatographymass spectrometry metabolic profile. Therefore, this study unfortunately cannot address the question of underlying mechanisms behind the associations found. Another limitation of this study is the failure to obtain a full data set; in particular, dietary data and OGTT results are available for a relatively small proportion. Additionally, missing data on fasting plasma glucose may have led to underestimation of both glucose intolerance and CFRD. Similarly, performing OGTT in patients younger than 9 years of age only if CFRD is clinically suspected may have resulted in the underestimation of CFRD and glucose intolerance. Finally, the observational character of the study only allows us to create hypotheses. However, our study clearly indicates that there is a need for intervention studies in order to determine whether the relationships between vitamin D and CFRD/HbA 1c values found in our study are causal.
Cystic fibrosis is a progressive disease. The risk of developing diabetes is higher with increasing age. Simultaneously, vitamin D absorption from the gut is agedependent. The possibility that the associations seen would mirror the natural progress of the disease can be ruled out since, in the MLR and logistic regression analyses, we corrected for age and even for lung function, a strong correlate of disease progression.
The currently recommended s25OHD concentration for the general population is ≥75 nmol/l. It is referred to as optimal and is based on parathyroid hormone response. The results of our study do not support the notion that s25OHD levels below 75 nmol/l are associated with higher HbA 1c values or CFRD diagnosis. However, only 16% of the cystic fibrosis patients included in our study had optimal s25OHD concentration. Therefore, the statistical analyses comparing this small group of patients with any other group might lack the statistical power necessary to detect any difference. The literature suggests that there is a steep decrease in HbA 1c level by increasing s25OHD up to 65 nmol/l and only smaller decreases with further increases in s25OHD [37] . Indeed, this study shows that s25OHD<30 nmol/l and even s25OHD<50 nmol/l are undisputedly associated with increased HbA 1c value and diabetes diagnosis, and therefore gives support for the notion that vitamin D insufficiency might play a role in the aetiology of diabetes.
A deviant OGTT curve in cystic fibrosis patients is considered to be a precursor of CFRD. Surprisingly, we did not see any association between OGTT result and vitamin D in the multivariate analyses. We speculate that this might be due to the fact that, unlike CFRD diagnosis, the OGTT result is largely dependent on current disease status, a variable that we did not correct for in the multivariate analyses. On the other hand, patients were in a stable condition with no ongoing exacerbation at inclusion. Thus, the missing association between OGTT result and vitamin D in our study might suggest that vitamin D is more strongly related to the risk of developing manifest diabetes than the risk of having isolated impaired glucose tolerance.
In conclusion, the present study supports the hypothesis that vitamin D insufficiency plays a role in the pathogenesis of impaired glucose tolerance and CFRD in cystic fibrosis patients. Degree of vitamin D insufficiency, s25OHD< 30 nmol/l and s25OHD<50 nmol/l were shown to be associated with higher HbA 1c values, and degree of vitamin D insufficiency as well as s25OHD<30 nmol/l were shown to be significant independent risk factors for CFRD diagnosis in the database of the Scandinavian Cystic Fibrosis Nutritional Study.
